HAVING A BALANCED MIX OF ONLINE & IN-PERSON MENTORING, PROFESSIONAL DEVELOPMENT AND SECOND OPINIONS
With
Dr Kieran Richardson (FACP)
Specialist Musculoskeletal Physiotherapist &
Director, Global Specialist Physiotherapy Pty Ltd
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Perth | October 2025
Dr. Kieran Richardson (FACP) is a Specialist Physiotherapist, conferred by the Australian College of Physiotherapists (Australian Physiotherapy Association) in 2016.
Dr Richardson is the Director of Global Specialist Physiotherapy, a consultancy company providing online Formal Mentoring and Professional Development individual clinicians, clinics, and groups, as well as Second Opinions to clinicians and directly to patients all around the world.
He has presented in state, national and international conferences, and has a special interest in evidence-based, non-surgical management of musculoskeletal conditions and recognition of these strategies within the Physiotherapy profession, as well as interprofessionally and to the general public.
Since the COVID-19 pandemic, his clinical role within Global Specialist Physiotherapy has shifted, whereby now he and his team offer primarily telehealth non-surgical second opinion consultations for patients with pain and injury locally in Australia and around the world.
He has conducted research into the biopsychosocial nature of musculoskeletal pain and injury, online information about the management of anterior cruciate ligament ruptures in Australia and is currently a part of an expert group of clinicians assisting the Australian Knee Injury Study through La Trobe University in Victoria.
Source: Supplied
-
Australian Healthcare and Hospitals Association (AHHA) Blueprint Refresh Roundtable
AHHA’s Blueprint Refresh Roundtable brings together AHHA members and other Australian health leaders to evaluate the progress made to date against Healthy people, healthy systems and to tease out key policy issues that need to be addressed in order to implement outcomes-focused, value-based care in Australia.
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
